KR20030032904A - 수지상 세포에 특이적인 항원-결합 단편, 단편을 사용한조성물 및 방법, 그것에 의해 인식된 항원, 및 그것에의해 얻어진 세포 - Google Patents
수지상 세포에 특이적인 항원-결합 단편, 단편을 사용한조성물 및 방법, 그것에 의해 인식된 항원, 및 그것에의해 얻어진 세포 Download PDFInfo
- Publication number
- KR20030032904A KR20030032904A KR1020027006247A KR20027006247A KR20030032904A KR 20030032904 A KR20030032904 A KR 20030032904A KR 1020027006247 A KR1020027006247 A KR 1020027006247A KR 20027006247 A KR20027006247 A KR 20027006247A KR 20030032904 A KR20030032904 A KR 20030032904A
- Authority
- KR
- South Korea
- Prior art keywords
- bdca
- cells
- antigen
- cell
- composition
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 342
- 108091007433 antigens Proteins 0.000 title claims abstract description 338
- 102000036639 antigens Human genes 0.000 title claims abstract description 338
- 230000027455 binding Effects 0.000 title claims abstract description 184
- 238000000034 method Methods 0.000 title claims abstract description 183
- 239000012634 fragment Substances 0.000 title claims abstract description 162
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 122
- 210000004027 cell Anatomy 0.000 title claims description 394
- 239000000203 mixture Substances 0.000 title claims description 140
- 238000012216 screening Methods 0.000 claims abstract description 9
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 claims description 232
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 claims description 229
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 110
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 claims description 109
- 102100026966 Thrombomodulin Human genes 0.000 claims description 109
- 108091033319 polynucleotide Proteins 0.000 claims description 94
- 239000002157 polynucleotide Substances 0.000 claims description 94
- 102000040430 polynucleotide Human genes 0.000 claims description 94
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 89
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 78
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- 230000014509 gene expression Effects 0.000 claims description 75
- 229920001184 polypeptide Polymers 0.000 claims description 74
- 206010028980 Neoplasm Diseases 0.000 claims description 69
- 241000282414 Homo sapiens Species 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 210000004369 blood Anatomy 0.000 claims description 41
- 239000008280 blood Substances 0.000 claims description 41
- 230000028993 immune response Effects 0.000 claims description 41
- 125000000539 amino acid group Chemical group 0.000 claims description 38
- 230000004044 response Effects 0.000 claims description 36
- 201000011510 cancer Diseases 0.000 claims description 33
- 102000004127 Cytokines Human genes 0.000 claims description 31
- 108090000695 Cytokines Proteins 0.000 claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 102000002227 Interferon Type I Human genes 0.000 claims description 28
- 108010014726 Interferon Type I Proteins 0.000 claims description 28
- 239000013598 vector Substances 0.000 claims description 26
- 230000001939 inductive effect Effects 0.000 claims description 22
- 210000002741 palatine tonsil Anatomy 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 20
- 239000011575 calcium Substances 0.000 claims description 20
- 239000002523 lectin Substances 0.000 claims description 20
- 239000003446 ligand Substances 0.000 claims description 20
- 102000004207 Neuropilin-1 Human genes 0.000 claims description 19
- 108090000772 Neuropilin-1 Proteins 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 230000004927 fusion Effects 0.000 claims description 19
- 201000009030 Carcinoma Diseases 0.000 claims description 18
- 206010022000 influenza Diseases 0.000 claims description 18
- 238000001890 transfection Methods 0.000 claims description 18
- 102000004388 Interleukin-4 Human genes 0.000 claims description 17
- 108090000978 Interleukin-4 Proteins 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 17
- 238000011161 development Methods 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 17
- 206010020751 Hypersensitivity Diseases 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 15
- 108020004999 messenger RNA Proteins 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 14
- 230000006698 induction Effects 0.000 claims description 14
- 239000003053 toxin Substances 0.000 claims description 14
- 231100000765 toxin Toxicity 0.000 claims description 14
- 108700012359 toxins Proteins 0.000 claims description 14
- 208000023275 Autoimmune disease Diseases 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 230000005867 T cell response Effects 0.000 claims description 12
- 230000007815 allergy Effects 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 12
- 230000003993 interaction Effects 0.000 claims description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 11
- 102000004856 Lectins Human genes 0.000 claims description 11
- 108090001090 Lectins Proteins 0.000 claims description 11
- 229910052791 calcium Inorganic materials 0.000 claims description 11
- 230000000295 complement effect Effects 0.000 claims description 11
- 244000045947 parasite Species 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 239000004472 Lysine Substances 0.000 claims description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
- 206010039491 Sarcoma Diseases 0.000 claims description 10
- 208000009956 adenocarcinoma Diseases 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 238000002372 labelling Methods 0.000 claims description 10
- 210000004185 liver Anatomy 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 108700024394 Exon Proteins 0.000 claims description 9
- 208000026935 allergic disease Diseases 0.000 claims description 9
- 230000001086 cytosolic effect Effects 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 210000001165 lymph node Anatomy 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
- 210000001185 bone marrow Anatomy 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 8
- 210000000952 spleen Anatomy 0.000 claims description 8
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- 102000013462 Interleukin-12 Human genes 0.000 claims description 7
- 108010065805 Interleukin-12 Proteins 0.000 claims description 7
- 108010002350 Interleukin-2 Proteins 0.000 claims description 7
- 102000000588 Interleukin-2 Human genes 0.000 claims description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 7
- 230000000890 antigenic effect Effects 0.000 claims description 7
- 230000003511 endothelial effect Effects 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 102000019034 Chemokines Human genes 0.000 claims description 6
- 108010012236 Chemokines Proteins 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- 102000003814 Interleukin-10 Human genes 0.000 claims description 6
- 108090000174 Interleukin-10 Proteins 0.000 claims description 6
- 208000000172 Medulloblastoma Diseases 0.000 claims description 6
- 230000036755 cellular response Effects 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 230000004962 physiological condition Effects 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- 239000013566 allergen Substances 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 230000016396 cytokine production Effects 0.000 claims description 5
- 230000001605 fetal effect Effects 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 230000028996 humoral immune response Effects 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 208000003455 anaphylaxis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 108700014844 flt3 ligand Proteins 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 230000006057 immunotolerant effect Effects 0.000 claims description 4
- 239000002596 immunotoxin Substances 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 4
- 210000003705 ribosome Anatomy 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 3
- 201000003076 Angiosarcoma Diseases 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 108090001008 Avidin Proteins 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 201000009047 Chordoma Diseases 0.000 claims description 3
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 3
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 claims description 3
- 208000005890 Neuroma Diseases 0.000 claims description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 3
- 208000007452 Plasmacytoma Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 208000008383 Wilms tumor Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 208000030961 allergic reaction Diseases 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 201000003714 breast lobular carcinoma Diseases 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 208000024207 chronic leukemia Diseases 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 210000002216 heart Anatomy 0.000 claims description 3
- 208000025750 heavy chain disease Diseases 0.000 claims description 3
- 201000002222 hemangioblastoma Diseases 0.000 claims description 3
- 230000002637 immunotoxin Effects 0.000 claims description 3
- 229940051026 immunotoxin Drugs 0.000 claims description 3
- 231100000608 immunotoxin Toxicity 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 206010024627 liposarcoma Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 208000012804 lymphangiosarcoma Diseases 0.000 claims description 3
- 206010027191 meningioma Diseases 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 208000025189 neoplasm of testis Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 3
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims description 3
- 201000010198 papillary carcinoma Diseases 0.000 claims description 3
- 230000005298 paramagnetic effect Effects 0.000 claims description 3
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000007363 trachea carcinoma Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 102000000589 Interleukin-1 Human genes 0.000 claims description 2
- 108010002616 Interleukin-5 Proteins 0.000 claims description 2
- 102000000743 Interleukin-5 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 206010027457 Metastases to liver Diseases 0.000 claims description 2
- 102000015439 Phospholipases Human genes 0.000 claims description 2
- 108010064785 Phospholipases Proteins 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 230000007910 cell fusion Effects 0.000 claims description 2
- 210000003850 cellular structure Anatomy 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 208000030355 pancreatic large cell neuroendocrine carcinoma Diseases 0.000 claims description 2
- 208000030312 pancreatic small cell neuroendocrine carcinoma Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims 7
- 230000020173 dendritic cell cytokine production Effects 0.000 claims 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 201000011199 bladder lymphoma Diseases 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 210000001020 neural plate Anatomy 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 201000005262 Chondroma Diseases 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 206010028665 Myxoedema Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 208000037828 epithelial carcinoma Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000003786 myxedema Diseases 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 claims 1
- 208000024724 pineal body neoplasm Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 12
- 210000005208 blood dendritic cell Anatomy 0.000 description 80
- 102100022297 Integrin alpha-X Human genes 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 40
- 238000010186 staining Methods 0.000 description 40
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 39
- 241000700159 Rattus Species 0.000 description 38
- 238000004519 manufacturing process Methods 0.000 description 36
- 210000004180 plasmocyte Anatomy 0.000 description 35
- 210000003719 b-lymphocyte Anatomy 0.000 description 31
- 238000011282 treatment Methods 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 108010002386 Interleukin-3 Proteins 0.000 description 26
- 102000000646 Interleukin-3 Human genes 0.000 description 26
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 24
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 24
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 24
- 238000011534 incubation Methods 0.000 description 24
- 210000001616 monocyte Anatomy 0.000 description 24
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 22
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 22
- 241000712461 unidentified influenza virus Species 0.000 description 22
- 230000006870 function Effects 0.000 description 21
- 239000002609 medium Substances 0.000 description 21
- 238000003752 polymerase chain reaction Methods 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 20
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 19
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 19
- 201000003232 brachydactyly type C Diseases 0.000 description 19
- 201000010276 collecting duct carcinoma Diseases 0.000 description 19
- 238000002560 therapeutic procedure Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000000684 flow cytometry Methods 0.000 description 17
- 230000000638 stimulation Effects 0.000 description 17
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 16
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 16
- 230000018109 developmental process Effects 0.000 description 16
- 238000009169 immunotherapy Methods 0.000 description 16
- 210000004698 lymphocyte Anatomy 0.000 description 16
- 230000001404 mediated effect Effects 0.000 description 15
- 239000011324 bead Substances 0.000 description 14
- 229940028885 interleukin-4 Drugs 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 13
- 230000012202 endocytosis Effects 0.000 description 13
- 210000004408 hybridoma Anatomy 0.000 description 13
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 12
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 102000003930 C-Type Lectins Human genes 0.000 description 11
- 108090000342 C-Type Lectins Proteins 0.000 description 11
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 11
- 108010047761 Interferon-alpha Proteins 0.000 description 11
- 102000006992 Interferon-alpha Human genes 0.000 description 11
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 11
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 11
- 239000012228 culture supernatant Substances 0.000 description 11
- 239000011325 microbead Substances 0.000 description 11
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 11
- 239000013615 primer Substances 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- -1 CD31 Proteins 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- 102000006354 HLA-DR Antigens Human genes 0.000 description 10
- 108010058597 HLA-DR Antigens Proteins 0.000 description 10
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 10
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 9
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 9
- 230000005291 magnetic effect Effects 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000035800 maturation Effects 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 7
- 102100035793 CD83 antigen Human genes 0.000 description 7
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 7
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000011712 cell development Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 230000016784 immunoglobulin production Effects 0.000 description 6
- 230000001506 immunosuppresive effect Effects 0.000 description 6
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 101100278839 Drosophila melanogaster sw gene Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 5
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 5
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 5
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 5
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 5
- 108010031099 Mannose Receptor Proteins 0.000 description 5
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 210000004727 amygdala Anatomy 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000002519 immonomodulatory effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 238000009448 modified atmosphere packaging Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- 102100025390 Integrin beta-2 Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
- 210000000447 Th1 cell Anatomy 0.000 description 4
- 210000004241 Th2 cell Anatomy 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 230000005784 autoimmunity Effects 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000010287 polarization Effects 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 description 3
- 101710183165 C-type lectin domain family 4 member K Proteins 0.000 description 3
- 101710125370 C-type lectin domain family 6 member A Proteins 0.000 description 3
- 102100040839 C-type lectin domain family 6 member A Human genes 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 206010058314 Dysplasia Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108091005250 Glycophorins Proteins 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 3
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 3
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 3
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 102100039564 Leukosialin Human genes 0.000 description 3
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 3
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 3
- 102000003729 Neprilysin Human genes 0.000 description 3
- 108090000028 Neprilysin Proteins 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 101150117115 V gene Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 238000000149 argon plasma sintering Methods 0.000 description 3
- 230000006472 autoimmune response Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 3
- 229950008454 favipiravir Drugs 0.000 description 3
- 210000004744 fore-foot Anatomy 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000005210 lymphoid organ Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 102100022749 Aminopeptidase N Human genes 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 2
- 102100023701 C-C motif chemokine 18 Human genes 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 2
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 102000053028 CD36 Antigens Human genes 0.000 description 2
- 108010045374 CD36 Antigens Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 238000002738 Giemsa staining Methods 0.000 description 2
- 102100035716 Glycophorin-A Human genes 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 102100028113 Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Human genes 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 2
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 2
- 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 description 2
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 101000916625 Homo sapiens Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Proteins 0.000 description 2
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 102100032999 Integrin beta-3 Human genes 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 2
- 101000749321 Mus musculus C-type lectin domain family 6 member A Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108050003978 Semaphorin Proteins 0.000 description 2
- 102000014105 Semaphorin Human genes 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 2
- 230000029662 T-helper 1 type immune response Effects 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 101710182532 Toxin a Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 230000003172 anti-dna Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 210000001821 langerhans cell Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 208000017830 lymphoblastoma Diseases 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 238000007898 magnetic cell sorting Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000019837 monoammonium phosphate Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 208000020053 Abnormal inflammatory response Diseases 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000795427 Anticla Species 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101100485276 Arabidopsis thaliana XPO1 gene Proteins 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101710090902 C-type lectin 2 Proteins 0.000 description 1
- 102100032557 C-type lectin domain family 1 member A Human genes 0.000 description 1
- 101710160443 C-type lectin domain family 1 member A Proteins 0.000 description 1
- 102100032529 C-type lectin domain family 1 member B Human genes 0.000 description 1
- 101710160442 C-type lectin domain family 1 member B Proteins 0.000 description 1
- 101710183461 C-type lectin domain family 4 member A Proteins 0.000 description 1
- 102100028667 C-type lectin domain family 4 member A Human genes 0.000 description 1
- 102100040841 C-type lectin domain family 5 member A Human genes 0.000 description 1
- 101710186546 C-type lectin domain family 5 member A Proteins 0.000 description 1
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108090000909 Collectins Proteins 0.000 description 1
- 102000004405 Collectins Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101000766908 Homo sapiens C-type lectin domain family 4 member A Proteins 0.000 description 1
- 101100222381 Homo sapiens CXCL11 gene Proteins 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101100341519 Homo sapiens ITGAX gene Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 101000759926 Homo sapiens Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 1
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001296119 Panteles Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 1
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 101100407739 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PET18 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 101710198343 Snaclec 2 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- CAWBRCOBJNWRLK-UHFFFAOYSA-N acetyloxymethyl 2-[4-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-3-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-5-methylphenoxy]ethoxy]phenyl]-1h-indole-6-carboxylate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C=2NC3=CC(=CC=C3C=2)C(=O)OCOC(C)=O)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O CAWBRCOBJNWRLK-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 201000006598 bladder squamous cell carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 210000004544 dc2 Anatomy 0.000 description 1
- 108010025838 dectin 1 Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000034964 establishment of cell polarity Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000001295 genetical effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000053234 human CLEC4A Human genes 0.000 description 1
- 102000057977 human CLEC4C Human genes 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 230000022023 interleukin-5 production Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 108010019677 lymphotactin Proteins 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 102000036209 mannose binding proteins Human genes 0.000 description 1
- 108020003928 mannose binding proteins Proteins 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- QCQYVCMYGCHVMR-AAZUGDAUSA-N n-[(2r,3r,4s,5r)-4,5,6-trihydroxy-1-oxo-3-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide Chemical compound CC(=O)N[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QCQYVCMYGCHVMR-AAZUGDAUSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 230000011364 negative regulation of type I interferon production Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108010082091 pre-T cell receptor alpha Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007974 regulation of B cell activation Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000008593 response to virus Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229940102127 rubidium chloride Drugs 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940002004 the magic bullet Drugs 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- C12N5/064—Immunosuppressive dendritic cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
Abstract
Description
H | 소수성 |
A | 지방족 |
C | 시스테인 |
G | 글리신 |
E | 글루탐산 |
W | 트립토판 |
△ | 방향족 아미노산 |
+ | 탄수화물의 칼슘-의존성 결합에 포함된 잔기 |
+P++ | 탄수화물-결합 특이성을 결정하는 영역 |
Claims (154)
- AC144, AD5-13A11, AD5-4B8, AD5-5EB, AD5-14H12 또는 AD5-8E7로 표시된 항체에 의해 특이적으로 인식되는 수지상 세포(DC)의 서브셋에 대해 특이적인, 분리된 항원-결합 단편을 포함하는 조성물.
- 제 1 항에 있어서, 항원-결합 단편은 AC144이거나, 또는 AC144로부터 유래되는 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 항원-결합 단편은 AD5-1311이거나, 또는 AD1311로부터 유래되는 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 항원-결합 단편은 AD5-4B8이거나, 또는 AD5-4B8로부터 유래되는 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 항원-결합 단편은 AD5-17F6이거나, 또는 AD5-17F6로부터 유래되는 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 항원-결합 단편은 AD5-5EB이거나, 또는 AD5-5EB로부터 유래되는 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 항원-결합 단편은 AD5-14H12이거나, 또는 AD5-14H12로부터 유래되는 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 항원-결합 단편은 AD5-8E7 이거나 AD5-8E7로부터 유래되는 것을 특징으로 하는 조성물.
- BDCA-2(SEQ ID NO:2)로 표시된 항원의 에피토프에 특이적인 항원 결합 단편을 포함하는 것을 특징으로 하는 조성물.
- BDCA-3으로 표시된 항원의 에피토프에 특이적인 항원 결합 단편을 포함하는 것을 특징으로 하는 조성물.
- 제 10 항에 있어서, BDCA-3은 100kD 단백질인 것을 특징으로 하는 조성물.
- 제 1 항 내지 제 11 항 중 어느 한 항에 따르는 조성물에 의해 특이적으로 인식되는 실질적으로 분리되거나 또는 농축된 세포 집단 또는 아집단.
- 세포 표면상의 뉴로필린-1의 동정에 의해 분리된 실질적으로 분리되거나 또는 농축된 DC 집단 또는 아집단.
- 제 13 항에 있어서, 뉴로필린-1은 BDCA-4에 특이적인 항체와 교차반응하는 항원-결합 단편에 의해 인식되는 것을 특징으로 하는 DC 집단 또는 아집단.
- 제 1 항 내지 제 11 항 중 어느 한 항에 있어서, 항원-결합 단편은 전 항체, 이중특이적 항체, 키메라 항체, Fab, F(ab')2, 단일 사슬 V 영역 단편(scFv), 융합 폴리펩티드, 압토머, 탄수화물 및 렉틴으로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제 15 항에 있어서, 항원-결합 단편은 사람 기원인 것을 특징으로 하는 조성물.
- 제 16 항에 있어서, 항원-결합 단편은 파지 전개 라이브러리에 의해 코딩되는 것을 특징으로 하는 조성물.
- 제 15 항에 있어서, 항원-결합 단편은 본질적으로 scFv로 구성되는 것을 특징으로 하는 조성물.
- 제 15 항에 있어서, 융합 펩티드는 화학적으로 기능적인 부분에 융합된 항원 -결합 단편을 포함하는 것을 특징으로 하는 조성물.
- 제 19 항에 있어서, 부분은 신호 펩티드, 면역 반응을 증진시키는 제제, 항원, 고체 지지체와의 커플링을 촉진시키는 제제, 생물반응 변형제, 면역독소, 독소, 검출가능한 표지, 상자성 표지 및 약물로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제 20 항에 있어서, 고체 지지체와의 커플링을 촉진시키는 제제는 바이오틴 및 아비딘으로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제 20 항에 있어서, 생물반응 변형제는 사이토카인 또는 케모카인인 것을 특징으로 하는 조성물.
- 제 20 항에 있어서, 사이토카인/케모카인은 IL-1, IL-2, IL-4, IL-5, IL-6, IL-12, 인터페론, TNF-α, IL-10 및 TGF-β로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제 20 항에 있어서, 독소는 리신, 방사성핵종, 억새풀 항바이러스 단백질, 녹농균 외독소 A, 디프테리아 독소, 리신 A 사슬, 진균 리보솜 불활성화 단백질 및 포스포리파제 효소로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제 20 항에 있어서, 검출가능한 표지는 방사성동위원소, 형광 화합물, 콜로이드상 금속, 화학발광 화합물, 생물발광 화합물, 효소, 기질, 보조인자 및 저해인자로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제 1 항 내지 제 25 항 중 어느 한 항에 있어서, 생리적으로 허용되는 부형제를 더 포함하는 것을 특징으로 하는 조성물.
- 실질적으로 모든 세포가 BDCA-1, BDCA-2 및 BDCA-3 중 적어도 1개를 발현하거나, 또는 BDCA-1, BDCA-2 및 BDCA-3 중 적어도 1개의 발현을 기초로 분리, 농축 또는 계수되는, 세포의 집단 또는 아집단.
- 제 27 항에 있어서, 적어도 80%의 세포가 BDCA-1+인 것을 특징으로 하는 조성물.
- 제 27 항에 있어서, 적어도 90%의 세포가 BDCA-1+인 것을 특징으로 하는 조성물.
- 제 27 항에 있어서, 적어도 95%의 세포가 BDCA-1+인 것을 특징으로 하는 조성물.
- 제 27 항에 있어서, 적어도 80%의 세포가 BDCA-2+인 것을 특징으로 하는 조성물.
- 제 27 항에 있어서, 적어도 90%의 세포가 BDCA-2+인 것을 특징으로 하는 조성물.
- 제 27 항에 있어서, 적어도 95%의 세포가 BDCA-2+인 것을 특징으로 하는 조성물.
- 제 27 항에 있어서, 적어도 80%의 세포가 BDCA-3+인 것을 특징으로 하는 조성물.
- 제 27 항에 있어서, 적어도 90%의 세포가 BDCA-3+인 것을 특징으로 하는 조성물.
- 제 27 항에 있어서, 적어도 95%의 세포가 BDCA-3+인 것을 특징으로 하는 조성물.
- 실질적으로 모든 세포가 BDCA-4를 발현하거나, 또는 BDCA-4의 발현을 기초로 분리, 농축 또는 계수되는, 수지상 세포의 집단 또는 아집단.
- 제 37 항에 있어서, 적어도 80%의 세포가 BDCA-4+인 것을 특징으로 하는 조성물.
- 제 37 항에 있어서, 적어도 90%의 세포가 BDCA-4+인 것을 특징으로 하는 조성물.
- 제 37 항에 있어서, 적어도 95%의 세포가 BDCA-4+인 것을 특징으로 하는 조성물.
- 세포가 실질적으로 활성화된 제 12 항 내지 제 14 항, 및 제 29 항 내지 제 40 항 중 어느 한 항의 수지상 세포.
- 제 12 항 내지 제 14 항, 및 제 28 항 내지 제 41 항 중 어느 한 항의 세포, 및 생리적으로 허용되는 부형제를 포함하는 조성물.
- 제 42 항에 있어서, 적어도 하나의 항원 또는 항원 펩티드(T 세포 에피토프)를 더 포함하는 것을 특징으로 하는 조성물.
- 제 43 항에 있어서, 항원은 세포에 로딩되는 것을 특징으로 하는 조성물.
- 제 43 항에 있어서, 항원은 세포와 함께 용액중에 있는 것을 특징으로 하는 조성물.
- 제 43 항에 있어서, 항원은 세포 표면에 존재하는 것을 특징으로 하는 조성물.
- 제 43 항에 있어서, 세포는 세포질 칼슘 농도를 조정(적어도 일시적으로)하도록 처리된 것을 특징으로 하는 조성물.
- 제 47 항에 있어서, 항원은 외인성으로 유래된 유전자 또는 mRNA에 의해 발현되는 것을 특징으로 하는 조성물.
- 제 48 항에 있어서, 세포는 BDCA-2에 특이적인 항원-결합 단편으로 전처리되는 것을 특징으로 세포.
- 제 49 항에 있어서, 항원은 종양 세포 항원, 바이러스 항원, 박테리아 항원, 기생충-유래 항원, 자기항원 및/또는 항원 펩티드(T 세포 에피토프)로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제 50 항에 있어서, 세포 및 항원 농도는 피험자에 투여시 피험자에서 면역 반응을 유도하는데 효과적인 것을 특징으로 하는 조성물.
- 제 51 항에 있어서, 면역 반응은 종양, 바이러스, 박테리아, 기생충 및 진균에 대해 지정되는 것을 특징으로 하는 조성물.
- 제 52 항에 있어서, 항원은 사람 종양 항원이며, 성상세포종, 섬유육종, 점액육종, 지방육종, 핍지교종, 상의세포종, 수모세포종, 초기 신경외배엽 종양 (PNET), 연골육종, 골원성육종, 췌장선암종, 소세포 및 대세포 폐선암종, 척삭종, 맥관육종, 내피육종, 편평세포암종, 기관지폐포성암종, 상피선암종, 및 그것의 간전이, 림프관육종, 림프관내피육종, 간암, 담관암종, 활막종, 중피종, 유잉 종양, 횡문근육종, 결장암종, 기저세포암종, 한선암종, 유두상암종, 피지선암종, 유두상선암종, 낭선종암종, 수질성암종, 기관지원성암종, 신세포암종, 담관암종, 융모막암종, 정상피종, 태생암종, 윌름 종양, 고환 종양, 수모세포종, 두개인두종, 상의세포종, 송과체종, 혈관모세포종, 청신경종, 핍지교종, 수막종, 신경모세포종, 망막모세포종, 백혈병, 다발성 골수종, 왈덴스트롬 마크로글로불린혈증, 및 중쇄병, 관 및 소엽 선암종과 같은 유방 종양, 자궁 경부의 편평 및 선암종, 자궁 및 난소 상피암종, 전립선 선암종, 방광의 이행성 편평세포암종, B 및 T 세포 림프종(소결절성 및 산재성), 형질세포종, 급성 및 만성 백혈병, 악성 흑생종, 연조직육종 및 평활근육종으로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제 49 항에 있어서, 항원은 면역관용원인 것을 특징으로 하는 조성물.
- 제 54 항에 있어서, 면역관용원은 자가면역 상태에 특이적인 것을 특징으로 하는 조성물.
- 제 49 항에 있어서, 자가면역 상태는 류마티스성 관절염, 연소성 류마티스성 관절염, 건선 관절염, 강직성 척추염, 쇼그렌 증후군, 홍반성 루푸스, 구드패스츄어 증후군, 라이터 증후군, 피부경화증, 혈관염, 다발성근염 및 피부근염으로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제 55 항에 있어서, 면역관용원은 기관 이식에 특이적인 것을 특징으로 하는 조성물.
- 제 56 항에 있어서, 기관 이식은 심장, 폐, 간, 골수, 간세포, 신장, 피부로구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 사람 세포의 혼합물을 분획내의 세포 중 적어도 80%가 BDCA-1+인 분획으로 분리하는 것을 포함하는, DC로 부화된 세포를 포함하는 조성물을 얻는 방법.
- 제 59 항에 있어서, 적어도 90%의 세포는 BDCA-1+인 것을 특징으로 하는 방법.
- 제 59 항에 있어서, 적어도 95%의 세포는 BDCA-1+인 것을 특징으로 하는 방법.
- 사람 세포의 혼합물을 분획내의 세포 중 적어도 80%가 BDCA-2+인 분획으로 분리하는 것을 포함하는, DC로 부화된 세포를 포함하는 조성물을 얻는 방법.
- 제 62 항에 있어서, 적어도 90%의 세포는 BDCA-2+인 것을 특징으로 하는 방법.
- 제 62 항에 있어서, 적어도 95%의 세포는 BDCA-2+인 것을 특징으로 하는 방법.
- 사람 세포의 혼합물의 분획내의 세포 중 적어도 80%가 BDCA-3+인 분획으로 분리하는 것을 포함하는, DC로 부화된 세포를 포함하는 조성물을 얻는 방법.
- 제 65 항에 있어서, 적어도 90%의 세포는 BDCA-3+인 것을 특징으로 하는 방법.
- 제 65 항에 있어서, 적어도 95%의 세포는 BDCA-3+인 것을 특징으로 하는 방법.
- 사람 세포의 혼합물을 분획내의 세포 중 적어도 80%가 BDCA-4+인 분획으로 분리하는 것을 포함하는, DC로 부화된 세포를 포함하는 조성물을 얻는 방법.
- 제 68 항에 있어서, 적어도 90%의 세포는 BDCA-4+인 것을 특징으로 하는 방법.
- 제 68 항에 있어서, 적어도 95%의 세포는 BDCA-4+인 것을 특징으로 하는 방법.
- a) 사람 세포의 혼합물을 얻는 단계b) BDCA-2로 표시된 항원에 특이적인 항원-결합 단편에 의해 특이적으로 인식되는 혼합물로부터 실질적으로 세포를 분리하는 단계를 포함하는, 실질적으로 순수한 세포 집단을 분리하는 방법.
- 제 71 항에 있어서, 항원 결합 단편은 AC144, AD5-13A11 또는 AD5-4B8이거나, 또는 이것으로부터 유래되는 것을 특징으로 하는 방법.
- a) 사람 세포의 혼합물을 얻는 단계; 및b) BDCA-3로 표시된 항원에 특이적인 항원-결합 단편에 의해 특이적으로 인식되는 혼합물로부터 실질적으로 세포를 분리하는 단계를 포함하는, 실질적으로 순수한 세포 집단을 분리하는 방법.
- 제 73 항에 있어서, 항원-결합 단편은 AD5-5E8 또는 AD5-14H12이거나, 또는 이것으로부터 유래되는 것을 특징으로 하는 방법.
- a) 사람 세포의 혼합물을 얻는 단계; 및b) BDCA-4로 표시된 항원에 특이적인 항원-결합 단편에 의해 특이적으로 인식되는 혼합물로부터 실질적으로 세포를 분리하는 단계를 포함하는, 실질적으로 순수한 DC 집단을 분리하는 방법.
- 제 75 항에 있어서, 항원-결합 단편은 AD5-17F6이거나, 또는 이것으로부터 유래되는 것을 특징으로 하는 방법.
- 제 63 항 내지 제 76 항 중 어느 한 항에 있어서, 세포의 공급원은 태아 골수, 신생아 골수, 성인 골수, 태아 간, 말초혈 및 탯줄혈, 류코페레시스, 활성화된 신선한 혈액, 배양 세포, 편도선, 비장, 림프절, 피부, 기도상피, 폐, 간, 소화관, 페이어반 및 비강으로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.
- 제 77 항에 있어서, 말초혈은 가동화되는 것을 특징으로 하는 방법.
- 제 77 항에 있어서, 가동화는 fLt3-리간드 및 G-CSF로 구성된 군으로부터 선택된 조성물을 사용한 전처리에 의한 것임을 특징으로 하는 방법.
- 제 77 항에 있어서, 가동화는 내인성 I형 인터페론 IL-12 및 IL-4를 유도하는 방법으로 구성된 군으로부터 선택된 조성물을 사용한 전처리에 의한 것임을 특징으로 하는 방법.
- a) 세포의 혼합물을 얻는 단계; 및b) BDCA-1, BDCA-2, BDCA-3 및 BDCA-4로 구성된 군으로부터 선택된 항원 중 어느 1개 이상에 특이적인 항원-결합 단편으로 세포를 표지하는 단계를 포함하는 세포 계수 방법.
- 제 81 항에 있어서, 항원은 BDCA-1인 것을 특징으로 하는 방법.
- 제 81 항에 있어서, 항원은 BDCA-2인 것을 특징으로 하는 방법.
- 제 81 항에 있어서, 항원은 BDCA-3인 것을 특징으로 하는 방법.
- 제 81 항에 있어서, 항원은 BDCA-4인 것을 특징으로 하는 방법.
- 실질적으로 순수한 DC의 집단 또는 아집단을 분리하는 단계; 및 DC의 세포질 칼슘 농도를 조정(적어도 일시적으로)하는 단계를 포함하는 DC의 면역 용량을 조정하는 방법.
- 제 86 항에 있어서, DC의 조정은 항원에 대한 Th1 반응을 우선적으로 유도하는 수지상 세포를 가져오는 것을 특징으로 하는 방법.
- 제 87 항에 있어서, 항원은 알레르기 항원, 바이러스 항원, 박테리아 항원, 종양 항원, 기생충 항원 및 진균 항원인 것을 특징으로 하는 방법.
- 제 86 항에 있어서, DC의 조정은 항원에 대한 Th2 반응을 우선적으로 유도하는 수지상 세포를 가져오는 것을 특징으로 하는 방법.
- 제 89 항에 있어서, 항원은 기생충, 자가항원, 박테리아 및 바이러스로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.
- 제 86 항에 있어서, DC의 조정은 항원에 대한 Th3/Th-R 반응을 우선적으로 유도하는 수지상 세포를 가져오는 것을 특징으로 하는 방법.
- 제 91 항에 있어서, 항원은 기생충, 자가항원, 박테리아 및 바이러스로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.
- BDCA-1, BDCA-2, BDCA-3 및 BDCA-4로 구성된 군으로부터 선택된 항원 중 어느 1개 이상의 항원에 특이적인 항원-결합 단편을 사용하여 실질적으로 순수한 세포의 집단 또는 아집단을 분리 또는 검출하거나, 또는 계수하는 단계; 시험 제제로 세포를 스크리닝하는 단계; 제제에 대한 세포 반응을 모니터링하는 단계; 세세제 대한 세포 반응과 대조표준 제제에 노출된 세포를 비교하는 단계; 및 시험 제제가 분리, 검출, 계수된 세포의 어떤 1가지의 면역 특성을 조정했는지의 여부를 측정하는 단계를 포함하는, 제약학적으로 효과적인 제제의 존재에 대해 시험 제제를 스크리닝하는 방법.
- 제 93 항에 있어서, 세포의 특성이 항원 표출, 사이토카인 생성, 사이토카인에 대한 반응, Th1 반응의 유도 또는 억제, Th2 반응의 유도 또는 억제, 내성을 유도하는 Th3/Th-R 반응 능력의 유도 또는 억제, 항원-특이적 반응의 유도, T 세포에서 아네르기의 유도, 애주번트 활성 및 적어도 일시적으로 세포내 칼슘을 가동화하는 시키는 능력으로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.
- 세포질 칼슘 농도를 변경시키거나(적어도 일시적으로), 또는 세포간 칼슘을 가동화하는 능력을 변경시키는 것을 포함하는, 수지상 세포의 면역 특성을 조정하는 방법.
- 제 95 항에 있어서, 조정은 생체내, 시험관내 및 생체외로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.
- 제 96 항에 있어서, 조정은 I형 인터페론에 의한 것임을 특징으로 하는 방법.
- 제 96 항에 있어서, 조정은 BDCA-1, BDCA-2, BDCA-3 및 BDCA-4로 구성된 군으로부터 선택되는 항원에 특이적인 항원-결합 단편의 결합에 의하거나, 또는 BDCA 에 결합하는 리간드의 저해에 의한 것임을 특징으로 하는 방법.
- 제 96 항에 있어서, 조정은 BDCA를 트리거링하거나, 또는 그것의 트리거링을 저해하는 것에 의한 것임을 특징으로 하는 방법.
- 제 1 항 내지 제 88 항 중 어느 한 항에 의해 얻어진 DC의 유효량을 치료가 필요한 피험자에게 투여하는 것을 포함하는, 생리적 상태를 치료하는 방법.
- 제 100 항에 있어서, 생리적 상태는 바이러스 감염인 것을 특징으로 하는 방법.
- 제 101 항에 있어서, 바이러스 감염은 간염, HIV, 인플루엔자, 리노바이러스, 헤르페스바이러스, 렌티바이러스, CMV 및 홍역으로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.
- 제 100 항에 있어서, 생리적 상태는 자가면역 질환인 것을 특징으로 하는 방법.
- 제 103 항에 있어서, 자가면역 질환은 SLE, 다발성 경화증, 관절염, 피부경화증 및 건선으로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.
- 제 100 항에 있어서, 생리적 상태는 알레르기 반응인 것을 특징으로 하는 방법.
- 제 105 항에 있어서, 알레르기 반응은 알레르기, 두드러기 및 아나필락시성 쇼크로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.
- 제 106 항에 있어서, 알레르기 반응은 천식인 것을 특징으로 하는 방법.
- 제 100 항에 있어서, 생리적 상태는 암인 것을 특징으로 하는 방법.
- 제 108 항에 있어서, 암은 성상세포종, 섬유육종, 점액육종, 지방육종, 핍지교종, 상의세포종, 수모세포종, 초기 신경외배엽 종양 (PNET), 연골육종, 골원성육종, 췌장선암종, 소세포 및 대세포 폐선암종, 척삭종, 맥관육종, 내피육종, 편평세포암종, 기관지폐포성암종, 상피선암종, 및 그것의 간전이, 림프관육종, 림프관내피육종, 간암, 담관암종, 활막종, 중피종, 유잉 종양, 횡문근육종, 결장암종, 기저세포암종, 한선암종, 유두상암종, 피지선암종, 유두상선암종, 낭선종암종, 수질성암종, 기관지원성암종, 신세포암종, 담관암종, 융모막암종, 정상피종, 태생암종, 윌름 종양, 고환 종양, 수모세포종, 두개인두종, 상의세포종, 송과체종, 혈관모세포종, 청신경종, 핍지교종, 수막종, 신경모세포종, 망막모세포종, 백혈병, 다발성 골수종, 왈덴스트롬 마크로글로불린혈증, 및 중쇄병, 관 및 소엽 선암종과 같은 유방 종양, 자궁 경부의 편평 및 선암종, 자궁 및 난소 상피암종, 전립선 선암종, 방광의 이행성 편평세포암종, B 및 T 세포 림프종(소결절성 및 산재성), 형질세포종, 급성 및 만성 백혈병, 악성 흑생종, 연조직육종 및 평활근육종으로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.
- BDCA-1, BDCA-2, BDCA-3 및 BDCA-4로 구성된 군으로부터 선택된 항원 중 어느 1개 이상에 특이적인 항원-결합 단편을 사용하여 실질적으로 순수한 수지상 세포의 집단 또는 아집단을 분리하는 단계; 및 수지상 세포 사이토카인 생성을 조정하는 제제로 세포를 처리하는 단계를 포함하는, 수지상 세포 사이토카인 생성을 조정하는 방법.
- 수지상 세포 사이토카인 생성을 조정하는 제제의 유효량을 치료가 필요한 피험자에게 투여하는 것을 포함하는, 수지상 세포 사이토카인 생성을 생체내에서 조정하는 방법.
- 항원으로 로딩되고, BDCA-1, BDCA-2, BDCA-3 및 BDCA-4로 구성된 군으로부터 선택된 항원 중 어느 1개 이상의 항원에 특이적인 항원-결합 단편을 사용하여 분리된, 실질적으로 순수한 수지상 세포의 집단 또는 아집단의 유효량을 면역 반응이 필요한 피험자에게 투여하는 것을 포함하며, 세포는 Th-1, Th-2 및 Th-3/Th-R로 구성된 군으로부터 선택된 반응을 유도하도록 조정되는, 항원에 특이적인 T 세포 및/또는 체액성 면역 반응을 생성하는 방법.
- 제 112 항에 있어서, 항원은 트랜스펙션, mRNA를 사용한 로딩, 및 세포 융합에 의해 로딩되는 것을 특징으로 하는 방법.
- 항원으로 로딩되고, BDCA-1, BDCA-2, BDCA-3 및 BDCA-4로 구성된 군으로부터 선택된 항원 중 어느 1개 이상의 항원에 특이적인 항원-결합 단편을 사용하여 분리된, 실질적으로 순수한 수지상 세포의 집단 또는 아집단의 유효량을 면역 반응이 필요한 피험자에게 투여하는 것을 포함하며, 세포는 Th-1, Th-2 및 Th-3/Th-R로 구성된 군으로부터 선택된 반응을 유도하도록 조정되는, 항원에 특이적인 T 세포 또는 체액성 면역 반응을 생성하는 방법.
- 제조합 숙주 세포에서 발현하고, 전체 재조합 숙주 세포 성분으로부터 발현된 폴리펩티드를 정제함에 의해 제조되며, SEQ ID NO:2로부터의 약 5개의 연속한아미노산 잔기를 포함하는 폴리펩티드.
- SEQ ID NO:2로부터의 약 5개의 연속한 아미노산 잔기를 포함하는 정제된 폴리펩티드를 포함하는 조성물.
- 제 116 항에 있어서, 폴리펩티드는 BDCA-2 세포외 도메인을 포함하는 것을 특징으로 하는 조성물.
- SEQ ID NO:2로부터의 5개 내지 50개의 연속한 아미노산 잔기로 구성된 정제된 펩티드.
- SEQ ID NO:2가 아닌 폴리펩티드 아미노산 서열에 연결된 폴리펩티드 아미노산 서열을 포함하고, 여기에서 이 아미노산 서열이 SEQ ID NO:2로부터의 약 5개의 연속한 아미노산 잔기를 포함하는 융합 단백질.
- SEQ ID NO:2로부터의 약 15개의 연속한 아미노산 잔기를 포함하는 것을 특징으로 하는 재조합 제 19 항에 따른 폴리펩티드.
- 제 120 항에 있어서, SEQ ID NO:2로부터의 약 30개의 연속한 아미노산 잔기를 포함하는 것을 특징으로 하는 재조합 폴리펩티드.
- 제 120 항에 있어서, SEQ ID NO:2로부터의 약 50개의 연속한 아미노산 잔기를 포함하는 것을 특징으로 하는 재조합 폴리펩티드.
- 폴리펩티드가 SEQ ID NO:2로부터의 약 15개의 연속한 아미노산 잔기를 포함하는 것을 특징으로 하는 제 122 항에 따른 조성물.
- 제 123 항에 있어서, 폴리펩티드가 SEQ ID NO:2로부터의 30개의 연속한 아미노산 잔기를 포함하는 것을 특징으로 하는 조성물.
- BDCA-2의 적어도 1개의 스플라이스 변이체를 포함하는 폴리펩티드.
- 제 125 항에 있어서, 스플라이스 변이체는 엑손 1 내지 6을 포함하는 것을 특징으로 하는 폴리펩티드.
- 제 126 항에 있어서, 스플라이스 변이체는 엑손 1, 3, 4, 5 및 6을 포함하는 것을 특징으로 하는 폴리펩티드.
- 제 126 항에 있어서, 스플라이스 변이체는 엑손 1, 2, 4, 5 및 6을 포함하는 것을 특징으로 하는 폴리펩티드.
- 제 126 항에 있어서, 스플라이스 변이체는 엑손 1, 2, 3, 5 및 6 을 포함하는 것을 특징으로 하는 폴리펩티드.
- BDCA-2 또는 그것의 단편을 코딩하는 폴리뉴클레오티드 또는 그것의 보체.
- 제 130 항에 있어서, SEQ ID NO:2로부터의 적어도 15개의 아미노산 잔기를 코딩하는 것을 특징으로 하는 폴리뉴클레오티드.
- 제 131 항에 있어서, SEQ ID NO:2로부터의 적어도 15 개의 아미노산 잔기를 코딩하는 것을 특징으로 하는 폴리뉴클레오티드.
- 제 131 항에 있어서, SEQ ID NO:2로부터의 적어도 30 개의 아미노산 잔기를 코딩하는 것을 특징으로 하는 폴리뉴클레오티드.
- 제 130 항에 있어서, SEQ ID NO:1을 가지는 것을 특징으로 하는 폴리뉴클레오티드.
- 제 130 항에 있어서, SEQ ID NO:1의 적어도 15개의 연속한 뉴클레오티드를 가지는 것을 특징으로 하는 폴리뉴클레오티드.
- 제 130 항에 있어서, SEQ ID NO:1의 적어도 75개의 연속한 뉴클레오티드를 가지는 것을 특징으로 하는 폴리뉴클레오티드.
- 제 130 항에 있어서, SEQ ID NO:1의 적어도 150개의 연속한 뉴클레오티드를 가지는 것을 특징으로 하는 폴리뉴클레오티드.
- BDCA-2의 적어도 1개의 스플라이스 변이체를 코딩하는 폴리뉴클레오티드.
- 제 138 항에 있어서, 스플라이스 변이체는 엑손 1 내지 6을 포함하는 것을 특징으로 하는 폴리뉴클레오티드.
- 제 138 항에 있어서, 스플라이스 변이체는 엑손 1, 3, 4, 5 및 6을 포함하는 것을 특징으로 하는 폴리뉴클레오티드.
- 제 138 항에 있어서, 스플라이스 변이체는 엑손 1, 2, 4, 5 및 6을 포함하는 것을 특징으로 하는 폴리뉴클레오티드.
- 제 138 항에 있어서, 스플라이스 변이체는 엑손 1, 2, 3, 5 및 6을 포함하는 것을 특징으로 하는 폴리뉴클레오티드.
- 프로모터에 기능적으로 부착된 것을 특징으로 하는 제 130 항 내지 제 142 항중 어느 한 항에 따른 폴리뉴클레오티드.
- 프로모터는 재조합 프로모터인 것을 특징으로 하는 제 130 항 내지 제 142 항중 어느 한 항에 따른 폴리뉴클레오티드.
- 폴리뉴클레오티드는 재조합 벡터내에 포함된 것을 특징으로 하는 제 130 항 내지 제 142 항 중 어느 한 항에 따른 폴리뉴클레오티드.
- 제 130 항 내지 제 142 항 중 어느 한 항의 폴리뉴클레오티드를 포함하는 재조합 숙주 세포.
- SEQ ID NO:2 또는 그것의 단편을 코딩하는 영역이 긴축 혼성화 조건하에서 SEQ ID NO:1 또는 그것의 보체에 혼성화하는 것을 특징으로 하는 130 항 내지 제 142 항 중 어느 한 항에 따른 폴리뉴클레오티드 또는 그것의 보체.
- BDCA 및 그것에 대한 리간드를 포함하는 조성물과 BDCA-2, BDCA-3 또는 BDCA-4와 리간드의 상호작용을 저해하는 제제의 유효량을 접촉시키는 것을 포함하는, BDCA와 그것에 특이적인 리간드의 상호작용을 저해하는 방법.
- 제 148 항에 있어서, DC와 T 세포의 상호작용은 DC 및 T 세포를 포함하는 조성물과 BDCA-2, BDCA-3 또는 BDCA-4와 T 세포의 상호작용을 저해하는 제제의 유효량을 접촉시킴에 의해 저해되는 것을 특징으로 하는 방법.
- 제 149 항에 있어서, 제제는 BDCA-2, BDCA-3 또는 BDCA-4에 특이적인 항원-결합 단편인 것을 특징으로 하는 방법.
- 제 150 항에 있어서, 제제는 생체내 또는 시험관내 투여되는 것을 특징으로 하는 방법.
- BDCA-2, BDCA-3 또는 BDCA-4와 피험자에서 염증을 감소시키는데 효과적인 T 세포의 상호작용을 저해하는 제제의 유효량을 치료가 필요한 피험자에게 투여하는 것을 포함하는 염증의 치료 방법.
- 세포에서 BDCA-2 안티센스를 발현하는 것을 포함하는, 세포에서 BDCA-2의 발현을 억제하는 방법.
- 제 130 항 내지 제 142 항 중 어느 한 항의 폴리뉴클레오티드를 포함하는 트랜스제닉 동물.
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16555599P | 1999-11-15 | 1999-11-15 | |
US60/165,555 | 1999-11-15 | ||
US16707699P | 1999-11-23 | 1999-11-23 | |
US60/167,076 | 1999-11-23 | ||
US17900300P | 2000-01-28 | 2000-01-28 | |
US60/179,003 | 2000-01-28 | ||
US18077500P | 2000-02-07 | 2000-02-07 | |
US60/180,775 | 2000-02-07 | ||
US19682400P | 2000-04-11 | 2000-04-11 | |
US60/196,824 | 2000-04-11 | ||
US19720500P | 2000-04-13 | 2000-04-13 | |
US60/197,205 | 2000-04-13 | ||
PCT/IB2000/001832 WO2001036487A2 (en) | 1999-11-15 | 2000-11-15 | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030032904A true KR20030032904A (ko) | 2003-04-26 |
KR100868235B1 KR100868235B1 (ko) | 2008-11-12 |
Family
ID=27558547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027006247A KR100868235B1 (ko) | 1999-11-15 | 2000-11-15 | 수지상 세포에 특이적인 항원-결합 단편, 단편을 사용한조성물 및 방법, 그것에 의해 인식된 항원, 및 그것에의해 얻어진 세포 |
Country Status (11)
Country | Link |
---|---|
EP (3) | EP1301539B1 (ko) |
JP (4) | JP5007007B2 (ko) |
KR (1) | KR100868235B1 (ko) |
CN (1) | CN1454215B (ko) |
AU (1) | AU785198B2 (ko) |
CA (2) | CA2664137C (ko) |
DE (1) | DE60033062T2 (ko) |
DK (1) | DK1301539T3 (ko) |
ES (1) | ES2280264T3 (ko) |
PT (1) | PT1301539E (ko) |
WO (1) | WO2001036487A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200130468A (ko) * | 2012-12-10 | 2020-11-18 | 바이오젠 엠에이 인코포레이티드 | 항-혈액 수지상 세포 항원 2 항체 및 이의 용도 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60033062T2 (de) * | 1999-11-15 | 2007-08-23 | Miltenyi Biotec Gmbh | Antikörper spezifisch für dendritische zellen, zusammensetzungen und verfahren, die diese antikörper verwenden, das durch die antikörper detektierte antigen und die dadurch erhaltenen zellen |
JP2004511254A (ja) * | 2000-10-16 | 2004-04-15 | バイエル アクチェンゲゼルシャフト | ヒト樹状細胞免疫受容体の調節 |
AU2002245593A1 (en) * | 2001-03-12 | 2002-09-24 | Lexicon Genetics Incorporated | Novel human dectin proteins and polynucleotides encoding the same |
US20030022249A1 (en) * | 2001-05-17 | 2003-01-30 | Juergen Schmitz | Antigen-binding fragments that recognize a subset of dendritic cells and methods of use thereof |
KR100522526B1 (ko) * | 2002-11-28 | 2005-10-19 | 주식회사 바이넥스 | 면역 치료용 수지상 세포의 제조방법 |
NZ554065A (en) * | 2004-10-07 | 2010-12-24 | Univ Zuerich | Use of an anti-interferon-alpha antibody for prevention and treatment of psoriasis |
CA2597265C (en) | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
BRPI0912570B8 (pt) | 2008-05-07 | 2021-05-25 | Argos Therapeutics Inc | anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos |
NZ593240A (en) * | 2009-01-06 | 2013-01-25 | Functional Genetics Inc | Random homozygous gene perturbation (rhgp) with thermal assymetric interlaced (tail)-pcr |
FR2968561B1 (fr) * | 2010-12-13 | 2013-08-09 | Lfb Biotechnologies | Utilisation d'un anticorps dirige contre une proteine membranaire |
US20150238632A1 (en) * | 2012-09-18 | 2015-08-27 | University Of Washington Through Its Center For Commercialization | Compositions and Methods for Delivery of Antigens to Plasmacytoid Dendritic Cells |
JP6685225B2 (ja) | 2013-12-16 | 2020-04-22 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 形質細胞様樹状細胞の枯渇 |
JP6604204B2 (ja) * | 2013-12-24 | 2019-11-13 | アステラス製薬株式会社 | 新規抗ヒトbdca−2抗体 |
JP6836500B2 (ja) * | 2014-05-16 | 2021-03-03 | ベイラー リサーチ インスティテュートBaylor Research Institute | 自己免疫状態および炎症状態を治療するための方法および組成物 |
EP3191109B1 (en) * | 2014-09-10 | 2023-03-29 | Miltenyi Biotec B.V. & Co. KG | A cell population for use in treating cancer |
WO2016089126A1 (ko) * | 2014-12-03 | 2016-06-09 | 사회복지법인 삼성생명공익재단 | 뉴로필린 1(Neuropilin 1)에 대한 항체 및 이의 용도 |
FR3034420A1 (fr) | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-cd303 |
FR3045386B1 (fr) * | 2015-12-16 | 2018-02-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation d'un anticorps dirige contre une proteine membranaire |
MD3529262T2 (ro) * | 2016-10-21 | 2022-01-31 | Inst Nat Sante Rech Med | Metode pentru promovarea răspunsului celulelor T |
FR3060394B1 (fr) * | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-amhrii |
FR3060395B1 (fr) * | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-her2 |
JP7158642B2 (ja) * | 2018-01-16 | 2022-10-24 | 国立大学法人山梨大学 | 質量分析装置及び質量分析システム |
WO2020227595A1 (en) * | 2019-05-09 | 2020-11-12 | Atara Biotherapeutics, Inc. | Clec4-targeted car-t-cells |
US20240018246A1 (en) * | 2020-12-03 | 2024-01-18 | Biogen Ma Inc. | Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus |
CN114264825B (zh) * | 2021-12-22 | 2023-08-15 | 重庆医科大学附属儿童医院 | 一种b淋巴细胞发育亚群免疫分型的方法和试剂盒 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10500492A (ja) * | 1995-03-15 | 1998-01-13 | ミルテニー バイオテク インク | 高勾配磁気細胞選別による造血樹状細胞の単離 |
US5871728A (en) * | 1995-03-31 | 1999-02-16 | University Of Pittsburgh | Method of regulating dendritic cell maturation |
US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
US6046158A (en) * | 1996-12-20 | 2000-04-04 | Board Of Regents The University Of Texas Systems | Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof |
ES2308808T3 (es) * | 1997-07-09 | 2008-12-01 | Schering Corporation | Genes de proteinas de membrana aislados de celulas dendriticas. |
FI973762A0 (fi) * | 1997-09-23 | 1997-09-23 | Krohn Kai | Ny gen |
WO1999021997A1 (en) * | 1997-10-28 | 1999-05-06 | Immunex Corporation | Viral encoded semaphorin protein receptor dna and polypeptides |
JP2002506645A (ja) * | 1998-03-17 | 2002-03-05 | シェーリング コーポレイション | 単離された哺乳動物膜タンパク質遺伝子および関連試薬 |
DE60033062T2 (de) * | 1999-11-15 | 2007-08-23 | Miltenyi Biotec Gmbh | Antikörper spezifisch für dendritische zellen, zusammensetzungen und verfahren, die diese antikörper verwenden, das durch die antikörper detektierte antigen und die dadurch erhaltenen zellen |
-
2000
- 2000-11-15 DE DE60033062T patent/DE60033062T2/de not_active Expired - Lifetime
- 2000-11-15 WO PCT/IB2000/001832 patent/WO2001036487A2/en active IP Right Grant
- 2000-11-15 CA CA2664137A patent/CA2664137C/en not_active Expired - Lifetime
- 2000-11-15 CN CN008198098A patent/CN1454215B/zh not_active Expired - Lifetime
- 2000-11-15 KR KR1020027006247A patent/KR100868235B1/ko active IP Right Grant
- 2000-11-15 EP EP00979855A patent/EP1301539B1/en not_active Expired - Lifetime
- 2000-11-15 CA CA2396428A patent/CA2396428C/en not_active Expired - Lifetime
- 2000-11-15 PT PT00979855T patent/PT1301539E/pt unknown
- 2000-11-15 ES ES00979855T patent/ES2280264T3/es not_active Expired - Lifetime
- 2000-11-15 EP EP07000097A patent/EP1783141A1/en not_active Ceased
- 2000-11-15 DK DK00979855T patent/DK1301539T3/da active
- 2000-11-15 JP JP2001538976A patent/JP5007007B2/ja not_active Expired - Lifetime
- 2000-11-15 AU AU17233/01A patent/AU785198B2/en not_active Expired
- 2000-11-15 EP EP06023310.3A patent/EP1813626B1/en not_active Expired - Lifetime
-
2007
- 2007-12-18 JP JP2007325800A patent/JP2008148700A/ja not_active Withdrawn
-
2011
- 2011-01-27 JP JP2011015018A patent/JP5355602B2/ja not_active Expired - Lifetime
-
2012
- 2012-03-01 JP JP2012045127A patent/JP5599834B2/ja not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200130468A (ko) * | 2012-12-10 | 2020-11-18 | 바이오젠 엠에이 인코포레이티드 | 항-혈액 수지상 세포 항원 2 항체 및 이의 용도 |
Also Published As
Publication number | Publication date |
---|---|
JP5355602B2 (ja) | 2013-11-27 |
JP2004512006A (ja) | 2004-04-22 |
JP2011092210A (ja) | 2011-05-12 |
CA2396428A1 (en) | 2001-05-25 |
CA2664137C (en) | 2012-09-25 |
DE60033062T2 (de) | 2007-08-23 |
JP2008148700A (ja) | 2008-07-03 |
CA2664137A1 (en) | 2009-07-16 |
DK1301539T3 (da) | 2007-05-21 |
EP1301539B1 (en) | 2007-01-17 |
WO2001036487A3 (en) | 2002-05-10 |
AU1723301A (en) | 2001-05-30 |
CN1454215B (zh) | 2013-01-02 |
EP1813626B1 (en) | 2015-02-18 |
EP1813626A1 (en) | 2007-08-01 |
EP1301539A2 (en) | 2003-04-16 |
PT1301539E (pt) | 2007-04-30 |
DE60033062D1 (de) | 2007-03-08 |
JP5599834B2 (ja) | 2014-10-01 |
WO2001036487A2 (en) | 2001-05-25 |
ES2280264T3 (es) | 2007-09-16 |
CN1454215A (zh) | 2003-11-05 |
AU785198B2 (en) | 2006-11-02 |
CA2396428C (en) | 2014-03-11 |
KR100868235B1 (ko) | 2008-11-12 |
JP2012152215A (ja) | 2012-08-16 |
JP5007007B2 (ja) | 2012-08-22 |
EP1783141A1 (en) | 2007-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200283499A1 (en) | Use of an antibody specific for BDCA 2 for ligation and removal of dendritic cells in the treatment systemic lupus erythematosis | |
KR100868235B1 (ko) | 수지상 세포에 특이적인 항원-결합 단편, 단편을 사용한조성물 및 방법, 그것에 의해 인식된 항원, 및 그것에의해 얻어진 세포 | |
Lee et al. | Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. | |
JP5560301B2 (ja) | 4ig−b7−h3およびその対応するnk細胞受容体を標的化する治療および診断方法ならびに組成物 | |
EA015009B1 (ru) | АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
CN101622275A (zh) | 提供疾患特异性结合分子和靶的方法 | |
CN1551783B (zh) | 类K121抗体在制备用于治疗κ类型多发性骨髓瘤的药物中的应用 | |
JPH10513347A (ja) | 組換え型ヒトα−フェトプロテインおよびその利用 | |
US20030022249A1 (en) | Antigen-binding fragments that recognize a subset of dendritic cells and methods of use thereof | |
CA2794123A1 (en) | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby | |
AU774651B2 (en) | Reduction of the immunogenicity of non-human grafts | |
CA2392400A1 (en) | A human normal counterpart of cd4+ cd56+ cutaneous neoplasm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121019 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131017 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20141023 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20151012 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160929 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20181018 Year of fee payment: 11 |